Of them, AR has been demonstrated to negatively regulate PD-L1 expression, and therefore lower AR-expressed tumors achieved a better response to immunotherapy in hepatocellular carcinoma (Jiang et al., 2020). This evidence concerns the gene AR and hepatocellular carcinoma.